GRM1 and early-onset autosomal dominant Alzheimer disease: The metabotropic glutamate receptor 1 (mGlu1) is one member of class C G protein-coupled receptors (GPCRs) and is considered to be a promising target to treat Alzheimer’s disease, anxiety, cancer, schizophrenia autism and chronic pain1, 2, 3.